Recombinant Ranpirnase enhances the expression of co-transfected mRNA by modulating cellular metabolic activity
Wu, X.; Chen, L.; Lei, Y.; Peng, X.; Zhang, Y.; Yang, G.; Yin, H.; Xu, K.
Show abstract
As the worlds first approved prophylactic mRNA vaccine, the development of the Covid-19 mRNA vaccine marks a milestone in mRNA therapeutics. However, achieving efficient transgene expression in therapeutic applications such as protein replacement and cancer therapeutical vaccines remains challenging. This study explores the use of recombinant Ranpirnase, a small ribonuclease, as a novel expression-enhancing tool for mRNA-based therapeutics. In Balb/c mice, co-expression of Ranpirnase significantly increased transgene expression levels by 3-to 6-fold and prolonged expression duration by more than 85%, regardless of mRNA nucleoside modification status. Recombinant Ranpirnase induces a cytostatic state in host cells, stabilizing mRNA and protein transcripts, thereby enhancing transgene expression. Importantly, co-expression of Ranpirnase recombinants did not cause detectable cytotoxicity or alter the tissue distribution of transgene expression, ensuring safety and tolerability at higher translation levels. The compact size of the recombinant Ranpirnase gene allows for seamless fusion with the target gene or co-transfection with existing delivery technologies. Altogether, recombinant Ranpirnase shows promise as an expression-enhancing element in mRNA-based therapeutics, including veterinary applications.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Optimizing C14120-based LNPs for in vitro and in vivo mRNA delivery 95%
- Biodistribution of mRNA vaccines in rats: Enrichment in injection site and lymph tissues and rapid clearance without tissue persistence 95%
- Single intravitreal administration of a tetravalent siRNA exhibits robust and efficient gene silencing in rodent and swine photoreceptors 94%
Similar papers in this journal
- Correlating physicochemical and biological properties to define critical quality attributes of a recombinant AAV vaccine candidate 94%
- Preclinical development of non-viral gene therapy for patients with advanced pancreatic cancer 94%
- A Thermostable, Flexible RNA Vaccine Delivery Platform for Pandemic Response 94%
Similar papers in this journal
- TLR7 and RIG-I dual-adjuvant loaded nanoparticles drive broadened and synergistic responses in dendritic cells in vitro and generate unique cellular immune responses in influenza vaccination 95%
- Advanced Peptide Nanoparticles Enable Robust and Efficient delivery of gene editors across cell types 95%
- Nanoparticle-delivered TLR4 and RIG-I agonists enhance immune response to SARS-CoV-2 subunit vaccine 95%
Similar papers in this journal
- Corticosteroids and cellulose purification improve respectively the in vivo translation and vaccination efficacy of self-amplifying mRNAs 95%
- Development of 5-FU-modified tumor suppressor microRNAs as a platform for novel microRNA-based cancer therapeutics 95%
- mRNA-LNP vaccines against Hepatitis B virus induce protective immune responses in preventive and chronic mouse challenge models 94%
Similar papers in this journal
- Intratumoral Delivered Novel Circular mRNA Encoding Cytokines for Immune Modulation and Cancer Therapy 96%
- Expression kinetics and innate immune response after electroporation and lipid nanoparticle mediated delivery of a self-amplifying mRNA in the skin of mice 93%
- RAB18 is a key regulator of GalNAc conjugated siRNA induced silencing in Hep3B cells 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.